Ronda Rippley

Senior Vice President, Quantitative Translational Pharmacology at Blueprint Medicines

Ronda Rippley has extensive work experience in the field of pharmacology and drug safety. Ronda currently holds the position of Vice President of Quantitative Pharmacology & Drug Safety at Blueprint Medicines since September 2021. Prior to that, they served as the Vice President and Head of Clinical Pharmacology at Constellation Pharmaceuticals from August 2020 to September 2021. Ronda also worked as an Associate Editor at Clinical and Translational Science (ASCPT family of journals) from June 2020 to August 2021.

Before joining Constellation Pharmaceuticals, Ronda worked as the Vice President of Clinical Pharmacology at Boston Pharmaceuticals from June 2019 to August 2020. Ronda also held the position of Senior Director and Head of Quantitative Pharmacology at Regeneron Pharmaceuticals, Inc. from May 2017 to June 2019.

Earlier in their career, Ronda worked at Merck for a significant period. Ronda served as the Executive Director & Quantitative Pharmacology and Pharmacometrics Therapy Area Head from July 2016 to May 2017. Prior to that, they held the position of Executive Director of Early Stage Quantitative Pharmacology & Pharmacometrics from November 2013 to June 2016. Ronda also worked as the US Lead for PK/PD from September 2011 to October 2013, and as the Director and Clinical PK/PD Site Lead from December 2007 to September 2011.

Before joining Merck, Ronda gained experience at Amgen as a Principal Scientist from July 2004 to August 2005, where they led PK scientific efforts for a clinical development program. Ronda also worked at Merck as a Sr. Research Pharmacokineticist/Research Fellow from December 1996 to June 2004.

Overall, Ronda Rippley has held various leadership positions and contributed significantly to the fields of quantitative pharmacology, clinical pharmacology, and drug safety throughout their career.

Ronda Rippley holds a PhD in Chemical Engineering from the University of Houston, which they obtained between 1992 and 1996. Prior to that, they completed a Master of Science in Chemical and Biochemical Engineering at the University of Pennsylvania from 1990 to 1992. Ronda Rippley's undergraduate degree in Chemical Engineering was earned at Montana State University-Bozeman, where they studied from 1986 to 1990. There is no available information about their education prior to attending Simmons University.

Links

Previous companies

Amgen logo
Boston Pharmaceuticals logo
Regeneron logo
Merck logo
Constellation Pharmaceuticals logo

Timeline

  • Senior Vice President, Quantitative Translational Pharmacology

    June 1, 2024 - present

  • Vice President, Quantitative Pharmacology & Drug Safety

    September, 2021